Alireza Pishgahi on Attenuation of Memory Impairment After Ischemia
Alireza Pishgahi, President at Novagena, shared on LinkedIn:
”I am proud to announce that our valuable study on Stroke Regeneration have been published.
Looking forward to bring it from bench to bedside.”
Stroke is the second leading cause of death globally, placing a heavy burden on both public health and economies.
This study explored the impact of autologous conditioned serum (ACS) on memory and related molecular factors in a mouse model of ischemic stroke.
The findings suggest that intranasal ACS treatment after stroke improves memory, likely by elevating IGF-1 levels, reducing inflammation via IL-1β inhibition, and regulating tau protein levels.
Read the full article here.
Article: Intranasal Autologous Conditioned Serum Attenuates Memory Impairment After mPFC Ischemia in Mice
Authors: Sareh Kazmi, Neda Yazdanfar, Fatemehsadat Seyedaghamiri, Alireza Pishgahi, Mehdi Yousefi, Tahereh Ghadiri, Saeed Sadigh-Eteghad, Mehdi Farhoudi
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 29, 2026, 13:22Cheryl Carcel: Make The Stroke Research More Inclusive for Women, Take The Survey
-
Jun 29, 2026, 13:18Bianca Rocca: New Expert Opinion On the Evolving Debate on Factor XI as a Therapeutic Target
-
Jun 29, 2026, 13:06Francisco Chacón-Lozsán: Intermittent Hemodialysis in the ICU Should not be Monitored Only by ‘Session Completed’
-
Jun 29, 2026, 13:01Edward Lee Carter: Exploring Anticoagulation Paradox
-
Jun 29, 2026, 12:55Salvatore Massimo Petrina: When is it Truly Safe to Stop Anticoagulation after AF Ablation?
-
Jun 29, 2026, 12:44Sumedha Dash: Inspiring the Next Generation of Voluntary Blood Donors at CV Raman Global University
-
Jun 29, 2026, 12:35Dilini Christina Ranasinghe: Behind Every Unit of Blood
-
Jun 29, 2026, 06:48Christina Pohlman: Anticoagulants and Bone Health – APS Awareness Month Day 23
-
Jun 29, 2026, 06:33Andreas Calatzis: Can Fibrinolysis Sensitivity Be Claimed Without a Reference Standard